What to do with a no-growth technology company that actually manages to grow? That is the conundrum facing HP Inc.’s investors.
NYS Entity Status
NYS Filing Date
DECEMBER 11, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC NOT-FOR-PROFIT CORPORATION
2013 - G&M PROPERTIES HP HOUSING DEVELOPMENT FUND COMPANY, INC.
AROUND THE WEB
- Growth Is the New HP Way, for Now
Thursday Aug 24, 2017
- Inside New York City’s Priciest Rentals
By CAROLINE BIGGS - Friday Sep 1, 2017
Some New Yorkers could afford to buy multimillion-dollar properties, but they’d rather rent a place for upward of $20,000 a month.
- Trump hires Chinese company to build newest golf club
By Mark Moore - Monday Sep 11, 2017
President Trump’s family business hired a construction company owned by the Chinese government to work on his golf club development in Dubai even though he vowed that he wouldn’t engage with foreign entities while in the White House, according to a report. DAMAC Properties, which is partnering with Trump on the project, inked a $32...
- New Development: Soft in the Middle, Splashy Up Top
By STEFANOS CHEN - Friday Sep 15, 2017
The luxury market in New York is pulling in two directions, with developers betting on big-ticket palatial aeries and million-dollar “starter” homes.
- Near The East River, Plans Emerge For NY’s Next Life Science Center
By Ben Fidler - Monday Aug 21, 2017
At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]